GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
therapeutic activity of GI-101 as a single agent or in combination with pembrolizumab,
lenvatinib or local radiotherapy (RT) over a range of advanced and/or metastatic solid
tumors.